Competing Endogenous RNA (ceRNA) Networks and Splicing Switches in Cervical Cancer: HPV Oncogenesis, Clinical Significance and Therapeutic Opportunities.
alternative splicing (AS)
cervical cancer (CC)
competing endogenous RNAs (ceRNAs)
human papillomavirus (HPV)
immunosuppression
low middle-income countries (LMICs)
protein arginine methyltransferases (PMRTs)
splicing disruptor drugs
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
16 Sep 2022
16 Sep 2022
Historique:
received:
02
08
2022
revised:
25
08
2022
accepted:
09
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
Cervical cancer (CC) is the primary cause of female cancer fatalities in low-middle-income countries (LMICs). Persistent infections from the human papillomavirus (HPV) can result in cervical cancer. However, numerous different factors influence the development and progression of cervical cancer. Transcriptomic knowledge of the mechanisms with which HPV causes cervical cancer pathogenesis is growing. Nonetheless, there is an existing gap hindering the development of therapeutic approaches and the improvement of patient outcomes. Alternative splicing allows for the production of numerous RNA transcripts and protein isoforms from a single gene, increasing the transcriptome and protein diversity in eukaryotes. Cancer cells exhibit astounding transcriptome modifications by expressing cancer-specific splicing isoforms. High-risk HPV uses cellular alternative splicing events to produce viral and host splice variants and proteins that drive cancer progression or contribute to distinct cancer hallmarks. Understanding how viruses utilize alternative splicing to drive pathogenesis and tumorigenesis is essential. Although research into the role of miRNAs in tumorigenesis is advancing, the function of other non-coding RNAs, including lncRNA and circRNA, has been understudied. Through their interaction with mRNA, non-coding RNAs form a network of competing endogenous RNAs (ceRNAs), which regulate gene expression and promote cervical cancer development and advancement. The dysregulated expression of non-coding RNAs is an understudied and tangled process that promotes cervical cancer development. This review will present the role of aberrant alternative splicing and immunosuppression events in HPV-mediated cervical tumorigenesis, and ceRNA network regulation in cervical cancer pathogenesis will also be discussed. Furthermore, the therapeutic potential of splicing disruptor drugs in cervical cancer will be deliberated.
Identifiants
pubmed: 36144454
pii: microorganisms10091852
doi: 10.3390/microorganisms10091852
pmc: PMC9501168
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : South African Medical Research Council
ID : 23108
Organisme : National Research Foundation
ID : 138139
Références
Cancer. 1981 Aug 15;48(4):899-903
pubmed: 7196794
Nat Commun. 2021 Mar 29;12(1):1946
pubmed: 33782401
Biomed Res Int. 2020 Nov 12;2020:3641231
pubmed: 33274204
Semin Cancer Biol. 2021 Oct;75:49-61
pubmed: 33035655
Front Oncol. 2019 Aug 02;9:682
pubmed: 31428574
Int J Mol Sci. 2022 Apr 27;23(9):
pubmed: 35563196
Int J Appl Basic Med Res. 2016 Apr-Jun;6(2):84-9
pubmed: 27127735
PLoS One. 2013 Jul 30;8(7):e70202
pubmed: 23936163
Biochem Biophys Res Commun. 2019 Jun 18;514(1):78-85
pubmed: 31023531
Gene. 2019 Dec 15;720:144099
pubmed: 31479715
J Cancer. 2022 Jan 1;13(2):541-553
pubmed: 35069901
Biomed Pharmacother. 2019 Sep;117:109133
pubmed: 31252264
J Low Genit Tract Dis. 2011 Jul;15(3):231-4
pubmed: 21543996
World J Biol Chem. 2014 May 26;5(2):115-29
pubmed: 24921003
Anticancer Drugs. 2020 Mar;31(3):272-281
pubmed: 31815762
J Adv Res. 2021 Sep 22;37:169-184
pubmed: 35499057
Biomed Res Int. 2018 Jun 19;2018:6242173
pubmed: 30018982
Mol Cell Probes. 2022 Aug;64:101829
pubmed: 35597500
EMBO Mol Med. 2016 May 02;8(5):442-57
pubmed: 26992833
Tumour Biol. 2017 Jun;39(6):1010428317705513
pubmed: 28631567
Gene. 2020 Apr 5;733:144273
pubmed: 31809842
Nat Rev Mol Cell Biol. 2019 Oct;20(10):642-657
pubmed: 31350521
Cell Physiol Biochem. 2018;48(1):173-184
pubmed: 30007986
Front Genet. 2021 Mar 23;12:618753
pubmed: 33833775
Oncogene. 2016 May 12;35(19):2413-27
pubmed: 26300000
Cancer Cell Int. 2019 Feb 28;19:45
pubmed: 30858762
Curr Probl Cancer. 2018 Sep;42(5):457-465
pubmed: 30064936
Pharmacoeconomics. 2017 Jan;35(1):65-82
pubmed: 27637758
Cancer Microenviron. 2011 Dec;4(3):361-75
pubmed: 21626415
Amino Acids. 2021 Apr;53(4):489-506
pubmed: 33404912
Br J Cancer. 2020 Jul;123(1):148-154
pubmed: 32336751
BMJ. 2018 Feb 27;360:k499
pubmed: 29487049
Ann Hepatol. 2020 May - Jun;19(3):269-279
pubmed: 32089501
Int J Biol Macromol. 2019 Jun 1;130:24-33
pubmed: 30790638
J Biochem. 2017 Jul 1;162(1):17-25
pubmed: 28057797
Syst Rev. 2021 Jun 21;10(1):180
pubmed: 34148552
Virus Res. 2017 Mar 2;231:83-95
pubmed: 27867028
Mol Cell. 2017 Jan 5;65(1):8-24
pubmed: 28061334
Aging (Albany NY). 2021 Feb 2;13(3):4663-4673
pubmed: 33534779
Front Oncol. 2022 Mar 04;12:841381
pubmed: 35311114
Cell Cycle. 2019 Dec;18(23):3313-3324
pubmed: 31590627
PeerJ. 2020 Sep 25;8:e10032
pubmed: 33033662
Exp Mol Med. 2021 May;53(5):788-808
pubmed: 34006904
Braz J Med Biol Res. 2020 Jan 13;53(1):e8883
pubmed: 31939597
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Cell Biol. 2017 Sep;19(9):1105-1115
pubmed: 28825698
Hereditas. 2021 Nov 10;158(1):44
pubmed: 34758879
Noncoding RNA. 2021 Aug 04;7(3):
pubmed: 34449657
Cancer Cell. 2019 Jul 8;36(1):100-114.e25
pubmed: 31257072
Vaccine. 2020 May 22;38(25):4066-4070
pubmed: 32362526
Medicine (Baltimore). 2019 Aug;98(34):e16922
pubmed: 31441876
BMC Cancer. 2021 Mar 18;21(1):289
pubmed: 33736612
Ann Transl Med. 2015 Dec;3(21):332
pubmed: 26734642
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):609-14
pubmed: 21215531
J Med Genet. 2015 Oct;52(10):710-8
pubmed: 26358722
Noncoding RNA. 2021 Mar 11;7(1):
pubmed: 33799493
Front Oncol. 2020 Feb 20;10:150
pubmed: 32154165
Mol Med Rep. 2019 May;19(5):3714-3722
pubmed: 30896864
Semin Cancer Biol. 2012 Aug;22(4):350-8
pubmed: 22465194
Am J Cancer Res. 2018 Jul 01;8(7):1176-1189
pubmed: 30094092
Wiley Interdiscip Rev RNA. 2019 Sep;10(5):e1543
pubmed: 31034770
J Biol Chem. 2015 May 22;290(21):13479-89
pubmed: 25847239
Theranostics. 2021 Aug 28;11(18):9162-9176
pubmed: 34522232
Cell Commun Signal. 2018 Feb 1;16(1):5
pubmed: 29391067
Kaohsiung J Med Sci. 2021 Jul;37(7):547-561
pubmed: 33728810
J Gen Virol. 2020 May;101(5):523-532
pubmed: 32182205
Cell Physiol Biochem. 2018;48(3):1355-1368
pubmed: 30048970
J Cell Biochem. 2019 Jun;120(6):10370-10379
pubmed: 30565744
Int J Oncol. 2016 Sep;49(3):943-52
pubmed: 27574106
J Exp Clin Cancer Res. 2021 Jan 6;40(1):11
pubmed: 33407694
J Transl Med. 2019 Nov 19;17(1):379
pubmed: 31744495
Signal Transduct Target Ther. 2020 Jun 19;5(1):102
pubmed: 32561709
Front Med (Lausanne). 2022 Jun 23;9:759928
pubmed: 35814779
Mol Oncol. 2022 Sep;16(18):3352-3379
pubmed: 35834102
Cancer Cell Int. 2018 May 08;18:70
pubmed: 29760583
Biomed Pharmacother. 2019 Jun;114:108790
pubmed: 30903920
Int J Cancer. 2018 Jan 15;142(2):224-229
pubmed: 28865151
Front Mol Biosci. 2018 Sep 07;5:80
pubmed: 30246013
Biomed Pharmacother. 2020 Jul;127:110209
pubmed: 32559848
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):4120-4130
pubmed: 31701767
Br J Cancer. 2022 May;126(8):1113-1124
pubmed: 34750493
Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17990-18000
pubmed: 31439820
Pharmazie. 2018 May 1;73(5):269-273
pubmed: 29724292
ACS Med Chem Lett. 2018 Apr 23;9(7):612-617
pubmed: 30034588
J Biol Chem. 2007 Nov 9;282(45):33009-21
pubmed: 17848568
Endocr Relat Cancer. 2012 Jul 22;19(4):509-26
pubmed: 22673335
Tumour Biol. 2016 Jan;37(1):633-40
pubmed: 26242259
Cell Cycle. 2019 Aug;18(15):1676-1686
pubmed: 31234694
Viruses. 2018 Jan 18;10(1):
pubmed: 29346309
Biomedicines. 2021 Dec 02;9(12):
pubmed: 34944633
Sci Rep. 2019 Aug 29;9(1):12556
pubmed: 31467383
Iran J Public Health. 2020 Nov;49(11):2179-2188
pubmed: 33708739
Front Genet. 2020 May 08;11:418
pubmed: 32457800
Cancer Med. 2020 Mar;9(5):1855-1866
pubmed: 31953923
Elife. 2022 Jan 05;11:
pubmed: 34984976
Biochem Biophys Res Commun. 2019 May 21;513(1):56-63
pubmed: 30935691
BMC Cancer. 2021 May 21;21(1):583
pubmed: 34020619
Oncotarget. 2017 Sep 23;8(49):86625-86633
pubmed: 29156822
J Cancer Res Ther. 2018;14(4):745-753
pubmed: 29970647
J Cancer. 2019 Jan 1;10(3):672-681
pubmed: 30719165
Cancer Discov. 2013 Oct;3(10):1113-21
pubmed: 24072616
Front Microbiol. 2018 Nov 28;9:2896
pubmed: 30546351
Exp Mol Pathol. 2019 Dec;111:104322
pubmed: 31655037
Cells. 2020 Jun 28;9(7):
pubmed: 32605220
Biosci Rep. 2019 Mar 15;39(3):
pubmed: 30833362
Oncol Lett. 2014 Jun;7(6):2135-2141
pubmed: 24932303
Cells. 2022 Mar 29;11(7):
pubmed: 35406713
J Oncol. 2021 Apr 7;2021:5529486
pubmed: 33880120
J Oncol. 2021 Oct 7;2021:4279039
pubmed: 34659409
Syst Rev. 2020 Apr 22;9(1):88
pubmed: 32321580
Nat Rev Cancer. 2013 Jan;13(1):37-50
pubmed: 23235912
Cell Death Dis. 2019 Dec 12;10(12):950
pubmed: 31831728
Cancer Biol Ther. 2018 May 4;19(5):391-399
pubmed: 29336659
J Cell Physiol. 2019 Aug;234(10):18985-18993
pubmed: 30932200
Front Cell Dev Biol. 2020 Aug 04;8:688
pubmed: 32850813
Mol Clin Oncol. 2015 Jul;3(4):851-858
pubmed: 26171195
Cancer Cell Int. 2021 Jul 28;21(1):400
pubmed: 34320988
Clin Microbiol Rev. 2003 Jan;16(1):1-17
pubmed: 12525422
Infect Agent Cancer. 2020 Apr 01;15:20
pubmed: 32266002
Genes (Basel). 2022 Jun 24;13(7):
pubmed: 35885916
BMC Infect Dis. 2020 Nov 25;20(1):889
pubmed: 33238902
Int J Mol Sci. 2021 Sep 18;22(18):
pubmed: 34576278
Front Genet. 2012 Oct 24;3:219
pubmed: 23109937
Front Oncol. 2020 Jan 31;10:48
pubmed: 32083005
Biochem Biophys Res Commun. 2018 Jun 22;501(2):428-433
pubmed: 29738762
EMBO Rep. 2017 Aug;18(8):1331-1351
pubmed: 28652379
Biomed Res Int. 2020 Mar 23;2020:4947381
pubmed: 32280688
Cancer Cell Int. 2020 Jun 08;20:221
pubmed: 32528230
Mol Cancer. 2014 Apr 28;13:92
pubmed: 24775712
Cell Biol Int. 2020 Dec;44(12):2416-2426
pubmed: 32808744
Biomed Pharmacother. 2018 Jun;102:749-757
pubmed: 29604594
IET Syst Biol. 2020 Dec;14(6):314-322
pubmed: 33399095
Gynecol Obstet Invest. 2019;84(6):562-567
pubmed: 31055567
BMC Cancer. 2019 Nov 28;19(1):1157
pubmed: 31779593
BMC Cancer. 2018 Jan 30;18(1):112
pubmed: 29382323
J Clin Oncol. 2007 Jul 10;25(20):2952-65
pubmed: 17617527
Nature. 2005 Jun 30;435(7046):1262-6
pubmed: 15988529